Renovaro Appoints Nathen Fuentes as Its New Chief Financial Officer
LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE)
Renovaro Inc. (NASDAQ: RENB), a pioneering company in cancer diagnostics and therapeutics powered by artificial intelligence, is pleased to announce the appointment of Nathen Fuentes, CPA, as Chief Financial Officer effective January 2, 2025, replacing interim CFO Simon Tarsh.
Nathen Fuentes Brings Extensive Experience in Leading Acquisition and Organic Growth Initiatives
Nathen Fuentes joins Renovaro with a deep understanding of the biotechnology and specialty healthcare industries, gained through progressively senior strategic, operational, and financial leadership roles. As a seasoned financial executive, Mr. Fuentes has experience leading acquisition and organic growth initiatives within highly leveraged environments while managing investor relations, human resources, finance, accounting, and revenue cycle functions.
Prior Experience of Nathen Fuentes
Prior to joining Renovaro, Mr. Fuentes served as Chief Financial Officer at Telomir Pharmaceuticals, an emerging leader in age-reversal science. He has also held senior leadership positions with mid-market private equity-sponsored companies within the specialty healthcare industry, including:
- Chief Financial Officer of Emergence Health Holdings: Mr. Fuentes was responsible for overseeing financial planning, budgeting, and forecasting, as well as managing investor relations and human resources.
- Divergent Dental Group: As CFO, Mr. Fuentes led acquisition and organic growth initiatives, while maintaining a strong focus on finance, accounting, and revenue cycle management.
- Family First Homecare and Dermatology Medical Partners: In these roles, Mr. Fuentes managed financial planning, budgeting, and forecasting, as well as investor relations and human resources.
Education and Professional Certifications
Nathen Fuentes earned his Bachelor of Science in Marketing from the University of Florida and his Master of Science in Accounting from Fairfield University. He is a Certified Public Accountant (CPA) and has completed various professional development courses to stay up-to-date with industry trends and best practices.
David Weinstein’s Comment on Nathen Fuentes’ Appointment
"We welcome Nathen to the position and are honored to have someone of his caliber and financial skill set serve as our CFO," said David Weinstein, Chief Executive Officer of Renovaro. "Nathen brings a dedicated work ethic and a proven track record in the biotechnology and healthcare industries. We believe his experience will be instrumental as we focus on revolutionizing healthcare by combining advanced diagnostic and personalized immunotherapy for early diagnosis, better-targeted treatments, and drug discovery."
Nathen Fuentes’ Comment on Joining Renovaro
"I am excited to be appointed as CFO as we prepare Renovaro to realize its potential to offer cancer patients early diagnosis, a treatment protocol, and recurrence monitoring," said Mr. Fuentes. "I look forward to working with David, the senior leadership team, and our finance team as we continue to execute on our strategic and financial priorities and our commitments to all shareholders."
About Renovaro
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube. For more information visit renovarogroup.com.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform, and fundraising.
- Success or Efficacy of Pipeline and Platform: The success or efficacy of our pipeline and platform is subject to various risks and uncertainties, including but not limited to regulatory approvals, market competition, and patent protection.
- Fundraising Efforts: Our ability to raise funds through public offerings or other means is subject to various risks and uncertainties, including but not limited to market conditions, investor sentiment, and regulatory requirements.
All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as ‘believes,’ ‘plans,’ ‘expects,’ ‘aims,’ ‘intends,’ ‘potential,’ or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC.
Investor Relations
For media inquiries, please contact:
- Chris Tyson: Executive Vice President, MZ Group – MZ North America
- Phone: 949-491-8235
- Email: RENBMZ@group.us
- Website: www.mzgroup.us
